Lamassu Biotech
Lamassu Biotech Presents Initial Safety and Pharmacokinetic Data for MDM2 Inhibitor SA53 from First-in-Human Phase 1/2a Study at ESMO Congress 2026
No dose-limiting toxicities and no Grade ≥2 treatment-emergent adverse events through four dose levels; Plasma exposures exceed those predicted by…